August 7, 2025 8:04am

A wall of cell and gene therapy sector volatility, just the usual anxiety and/or plead ignorant with an avoidance pill?

Earnings <Last night – Wednesday> Sarepta Therapeutics (SRPT) <see The Bottom line>

Pre-Open Signals: 4 Positive and 1 Sell into Strength Indications

BREAKING: Nonfarm payrolls growth totaled 73 K for July, above the June total of 14 K but below even the meager Dow Jones estimate for a gain of 100 K. June and May totals were revised sharply lower, <June and May totals were revised sharply lower, down by a combined 258 K from previously announced levels> down by a combined 258 K from previously announced levels. The June total came down from the previously stated 147 K, while the May count fell to just 19 K, revised down by 125 K.The weak report, including the dramatic revisions, could provide incentive for the Fed to lower interest rates when meeting in September. Health care and social assistance combined for some 94% of the job growth. The unemployment rate rose to 4.2%, in line with the forecast.

Earnings today: Prime Medicine (PRME), Intellia Therapeutics (NTLA) and Regenxbio (RGNX)

On point, short on words, long on informing facts and being judicious!

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

There are buying opportunities and sell signals, but many names are likely to reverse direction after the open, especially following earnings.

My “posts” are conveyed with a simplicity of language to highlight what is informative.

 

Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: An undertow depleted the sector … https://www.regmedinvestors.com/articles/14051

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Thursday: The pre-open Dow futures are UP +0.49% or (+221 points), the S&P futures are UP +0.57% or (+36 points) and the Nasdaq futures are UP +0.69% or (+162 point)

  • US stock futures edged higher on Thursday
  • European stocks broadly higher amid more tariff news,
  • Asia markets closed mostly higher.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Wednesday: The Dow closed UP +81.38 points or +0.18%, the S&P closed UP +45.87 points or +0.73% while the Nasdaq closed UP +252.87 points or +1.21%
  • Tuesday: The Dow closed DOWN -61.90 points or -0.14%, the S&P closed DOWN -30.77 points or -0.49% while the Nasdaq closed DOWN -137.03 points or -0.65%
  • Monday: The Dow closed UP +585.06 points or +1.34%, the S&P closed UP +91.93 points or +1.47% while the Nasdaq closed UP +403.45 points or +1.95%
  • Week to date, the S&P 500 has gained 1.7%, the Nasdaq has added 2.5% and the Dow has advanced 1.4%.
  • The past week, the Dow tumbled -2.9% <its worst week since April 4>, the S&P 500 dropped -2.4% <for its worst weekly performance since May 23> and the Nasdaq lost -2.2

Economic Data Docket: Many and subsets of Initial jobless claims, U.S. productivity, U.S. unit-labor, Wholesale inventories, Atlanta Fed President Raphael Bostic speech and to end the session Consumer credit.

 

Q3 – August - 3 negative and 1 positive closes

  • July – 1 market holiday, 13 positive and 9 negative closes

 

Coverage Dropped: bluebird bio (BLUE) Private Equity acquired, Blueprint Medicine (BPMC) acquired by SNY, Homology Medicine (FIXX), Sage Therapeutics (SAGE) acquired by SUPN, Verve Therapeutics (VERV) – acquired by LLY

Added: BioNTech (BNTX), Sarepta Therapeutics (SRPT), Supernus Pharma (SUPN), IQVIA Holdings (IQV) and Wave Life Sciences Ltd. (WVE)

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • I’ll pass; …. an escape in the making of more earnings releases, econs, ups, downs and just plain uncertainty

Although:

BioNTech (BNTX) +$0.23 after Tuesday’s +$1.04 after Monday’s +$2.69 with a positive +$0.70 or +0.63% pre-open

CRISPR Therapeutics (CRSP) closed up +$0.75 after Tuesday’s -$4.00 after Monday’s +$3.50 with a positive +$0.95 or +1.69% pre-open

Moderna (MRNA) closed down -$0.76 after Tuesday’s -$0.17 with a positive +$0.20 or +0.75% pre-open

Sarepta Therapeutics (SRPT) closed down -$0.49 pre-earnings release with a positive +$1.94 or +11.93% pre-open

Alnylam Pharmaceuticals (ALNY) closed up +$9.23 after Tuesday’s -$0.64 after Monday’s +$17.76 with a positive +$0.36 or +0.08% pre-open – SELL into Strength

 

The BOTTOM LINE: Seeing “green on the screen”, but not much in the aftermarket and pre-market…

August began as July ended: understand the “flow” …

  • 8/6 – Wednesday closed negative with 11 positive, 22 negative and 2 flats
  • 8/5 – Tuesday closed negative with 15 positive, 19 negative and 1 flat
  • 8/4 – Monday closed positive with 27 positive, 8 negative and 0 flats
  • 8/1 – Friday closed negative with 9 positive, 20 negative and 6 flats

Last Week:

  • 7/31 - Thursday closed negative with 3 positive, 25 negative and 7 flats
  • 7/30 - Wednesday closed negative with 12 positive, 18 negative and 5 flats
  • 7/29 – Tuesday closed negative with 8 positive, 22 negative and 5 flats
  • 7/28 – Monday closed negative with 14 positive, 16 negative and 5 flats

 

More Earnings are due: 

8/11, Monday = Agenus (AGEN)

  • Meeting earnings expectation and/or missing consensus will deem share pricing outcomes this week.

 

Earnings to date:

  • Sarepta Therapeutics (SRPT) a net income of +$196.9 M or -$1.89 per share, revenue of $611.1 M, a cash position of $850.3 M and a runway until 2027
  • Voyager Therapeutics (VYGR) a net loss of -$33.4 M or -$0.57 per share, revenue of $5.2 M, a cash position of $262 M with a runway until 2028
  • Supernus Pharma (SUPN) a net income of +$22.5M or +$0.40 per share with revenue of $165.5 M, a cash position of $522.6 and a runway beyond 2028
  • Ultragenyx Pharmaceuticals (RARE) a net loss of -$114.9 M or -$1.17 per share, revenue of $166.5 M, a cash position of $339 M with a runway until 2027
  • Beam Therapeutics (BEAM) a net loss of -$102.3M or -$1.00 per share with revenue of $8.7 M, a cash position of $1.2 B and a runway beyond 2028
  • AxoGen (AXGN) a net income of +$579 K or +0.01 per share, revenue of $56.7 M, a cash position of $35.9 M with a runway until 2026
  • Cellectis SA (CLLS) a net loss of -$18.1 M or -$0.24 per share, revenue of $30.2 M, a cash position of $230 M and a runway until 2H/27.
  •  CRISPR Therapeutics (CRSP) a net loss of -$208.5 M or -$2.40 per share, revenue of $45.2 M, a cash position of $1.7 B and a N/A runway
  • Moderna (MRNA) a net loss of -$0.8 B, or -$2.13 per share with revenue of $142 M, an R&D and an SG&A decrease and a cash position of $7.5 B with a runway until 2026 <beats revenue estimate and earnings consensus>.
  • Sage Therapeutics (SAGE): net loss of -$49.7 M or -$0.79 per share, revenue of $23.2M, a cash position of $366 M – acquired
  • Vericel (VCEL): net loss of -$0.06 M or -$0.01 per share, revenue of $63.2M, a cash position of $164 M and a runway until 2027
  • Alnylam Pharmaceuticals (ALNY): net loss of -$66.3 M or -$0.51 per share, revenue of $773.7 M, a cash position of $2.86 B and a N/A runway
  • Lenz Therapeutics (LENZ): net loss of -$14.9 M or -$0.53 per share, revenue of $5 M, a cash position of $209.6 M and a runway until 2026
  • uniQure NV (QURE): a net loss of -$37.7 M, or -$0.69 per share with revenue of $5.3 M, an R&D increase and an SG&A decrease and a cash position of $377.7 M with a runway until 2H/27 <missed revenue estimate and consensus>
  • Ionis Pharmaceuticals (IONS): a net income of +124 M, or +$0.70 per share with revenue of $452 M, and a cash position of $2.3 B with a runway until FY28 < estimate and consensus beats>
  • MiMedx (MDXG): a net income of +$100 M or +$0.06 per share with revenue of $99 M and a cash position of $100 M with a runway until 2026.

 

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • As always, I brace myself for earnings associated with share pricing volatility, some economics and tariff developments and their effects?

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.